References
- Kuehn BM. Accelerated overdose deaths linked with COVID-19. JAMA. 2021;325:523.
- Olfson M, Zhang V, Schoenbaum M, King M. Trends in buprenorphine treatment in the United States, 2009-2018. JAMA. 2020;323:276–77.doi:https://doi.org/10.1001/jama.2019.18913.
- Dhingra L, Ahmed E, Shin J, Scharaga E, Magun M. Cognitive effects and sedation. Pain Med. 2015 Oct;16:S37–43. doi:https://doi.org/10.1111/pme.12912.
- Wang GY, Wouldes TA, Russell BR. Methadone maintenance treatment and cognitive function: a systematic review. Curr Drug Abuse Rev. 2013 Sep;6:220–30. doi:https://doi.org/10.2174/18744737112059990020.
- Elkana O, Adelson M, Sason A, Doniger GM, Peles E. Improvement in cognitive performance after one year of methadone maintenance treatment. Psychiatry Res. 2020 Dec;294:113526. doi:https://doi.org/10.1016/j.psychres.2020.113526.
- Phan HM, Yoshizuka K, Murry DJ, Perry PJ. Drug testing in the workplace. Pharmacotherapy. 2012;32:649‐656.doi:https://doi.org/10.1002/j.1875-9114.2011.01089.x.
- Executive order 12564–Drug-free Federal workplace. [accessed 15 Jan 2021]. https://www.archives.gov/federal-register/codification/executive-order/12564.html.
- Drug-Free Workplace Programs. Substance Abuse and Mental Health Services Administration (SAMHSA). [accessed 16 Jan 2021]. https://www.samhsa.gov/workplace.
- Hamza H, Bryson EO. Buprenorphine maintenance therapy in opioid-addicted health care professionals returning to clinical practice: a hidden controversy. Mayo Clin Proc. 2012 Mar;87:260–67. doi:https://doi.org/10.1016/j.mayocp.2011.09.007.
- Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13:93–103. doi:https://doi.org/10.1097/ADM.0000000000000457.
- Hickman M, Steer C, Tilling K, Lim AG, Marsden J, Millar T, Strang J, Telfer M, Vickerman P, Macleod J. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction. 2018 Aug;113:1461–76. doi:https://doi.org/10.1111/add.14188.
- Velander JR. Suboxone: rationale, science, misconceptions. Ochsner J. 2018;18:23–29.
- Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction. 2014 Jan;109:79–87. doi:https://doi.org/10.1111/add.12333.
- Strand MC, Fjeld B, Arnestad M, Mørland J. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration. Traffic Inj Prev. 2013;14:26–38.doi:https://doi.org/10.1080/15389588.2012.689451.
- Soyka M, Lieb M, Kagerer S, Zingg C, Koller G, Lehnert P, Limmer C, Kuefner H, Hennig-Fast K. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharmacol 2008 Dec;28:699–703. doi:https://doi.org/10.1097/JCP.0b013e31818a6d38.
- Schindler SD, Ortner R, Peternell A, Eder H, Opgenoorth E, Fischer G. Maintenance therapy with synthetic opioids and driving aptitude. Eur Addict Res. 2004;10:80–87.doi:https://doi.org/10.1159/000076118.
- Soyka M. Opioids and traffic safety–focus on buprenorphine. Pharmacopsychiatry 2014 Jan;47:7–17. doi:https://doi.org/10.1055/s-0033-1358707.
- Stephenson J. Drug overdose deaths head toward record number in 2020, CDC warns. JAMA Health Forum. 2020;1:e201318.doi:https://doi.org/10.1001/jamahealthforum.2020.1318.
- Beletsky L, Wakeman SE, Fiscella K. Practicing what we preach - ending physician health program bans on opioid-agonist therapy. N Engl J Med. 2019 Aug 29;381:796–98. doi:https://doi.org/10.1056/NEJMp1907875.
- Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004 Mar;92:294–303. quiz 303-5, 355. Erratum in: Ann Allergy Asthma Immunol. 2004 Jun;92(6):675. Erratum in: Ann Allergy Asthma Immunol. 2005 Mar;94(3):409–10. doi:https://doi.org/10.1016/S1081-1206(10)61566-9
- Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2019 Dec;24:1868–83. doi:https://doi.org/10.1038/s41380-018-0094-5.